Hematologic malignancies (HM) start in blood forming tissue or in the cells of the immune system. Cyclin-dependent kinases (CDKs) regulate cell cycle progression, and some of them control cellular transcription. CDK inhibition can trigger apoptosis and could be particularly useful in hematological malignancies. Herein, we describe our efforts toward the discovery of a novel series of quinazoline derivatives as CDK inhibitors. Intensive structural modifications lead to the identification of compound 37d as the most active inhibitors of CDKs 1, 2, 4, 8 and 9 with balancing potency and selectivity against CDKs. Further biological studies revealed that compound 37d can arrest the cell cycle and induce apoptosis via activating PARP and caspase 3. More importantly, compound 37d showed good antitumor efficacy in multiple HM mice xenograft models with no obvious toxicity. These results indicated that CDK 1, 2, 4, 8, and 9 inhibitors could be potentially used to treat certain hematologic malignancies.

中文翻译：

---

N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine 的新发现抗血液系统恶性肿瘤的强效口服细胞周期蛋白依赖性激酶抑制剂

血液系统恶性肿瘤 (HM) 始于造血组织或免疫系统细胞。细胞周期蛋白依赖性激酶 (CDK) 调节细胞周期进程，其中一些控制细胞转录。CDK 抑制可以触发细胞凋亡，并且在血液系统恶性肿瘤中可能特别有用。在此，我们描述了我们为发现作为 CDK 抑制剂的一系列新型喹唑啉衍生物所做的努力。密集的结构修饰导致化合物37d被鉴定为CDK 1、2、4、8 和 9 最活跃的抑制剂，同时平衡了针对 CDK 的效力和选择性。进一步的生物学研究表明，化合物37d可以通过激活 PARP 和 caspase 3 来阻止细胞周期并诱导细胞凋亡。更重要的是，化合物37d在多种 HM 小鼠异种移植模型中显示出良好的抗肿瘤功效，无明显毒性。这些结果表明 CDK 1、2、4、8 和 9 抑制剂可潜在用于治疗某些血液系统恶性肿瘤。